Novo Nordisk Sues Hims & Hers Over Semaglutide Patent Infringement
Novo Nordisk has initiated a patent infringement lawsuit against Hims & Hers Health, accusing it of deploying copycat weight-loss drug formulations that infringe on its semaglutide patents. The legal action, coupled with Hims & Hers’ delayed low-cost semaglutide pill launch, may safeguard Novo Nordisk’s market share in GLP-1 therapies and protect its revenue stream from emerging competitors.
1. Lawsuit Filed Over Semaglutide Patents
Novo Nordisk filed a patent infringement suit against Hims & Hers Health, alleging that the telehealth company’s weight-loss drug formulations unlawfully copy its semaglutide technology. The complaint asserts that Hims & Hers’ upcoming low-cost semaglutide pill launch infringes on key patents covering active ingredient design and delivery mechanisms.
2. Implications for Market Position
The lawsuit arrives as Hims & Hers faces delays in its semaglutide pill rollout, potentially strengthening Novo Nordisk’s dominance in the GLP-1 weight-loss market. Successful enforcement could deter competitors, maintain Novo Nordisk’s premium pricing and reinforce its global revenue trajectory in obesity and diabetes therapies.